Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia

被引:65
|
作者
Stevens, SJC
Verkuijlen, SAWM
Hariwiyanto, B
Harijadi
Fachiroh, J
Paramita, DK
Tan, IB
Haryana, SM
Middeldorp, JM
机构
[1] Free Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands
[3] Gadjah Mada Univ, Yogyakarta, Indonesia
关键词
D O I
10.1128/JCM.43.7.3066-3073.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia and is strongly associated with Epstein-Barr virus (EBV). We investigated the primary diagnostic value of circulating EBV DNA and anti-EBV immunoglobulin G (IgG) and IgA levels in Indonesian NPC patients (n = 149). By a 213-bp Epstein-Barr virus nuclear antigen 1 (EBNA1)-based real-time LightCycler PCR, 72.5% of patients were positive for EBV DNA in whole blood, with 29.5% having levels above a previously determined clinical cutoff value (COV) of 2,000 EBV DNA copies/ml, the upper level in healthy carriers. In a 99-bp LightCycler PCR, 85.9% of patients were positive and 60.4% had levels above the COV. This assay quantified a significantly higher EBV load than the 213-bp PCR assay (P < 0.0001), suggesting that circulating EBV DNA is fragmented. Using data from 11 different studies, we showed a significant inverse correlation between PCR amplicon size and the percentage of patients positive for circulating EBV DNA (Spearman's rho = -0.91; P < 0.0001). EBV DNA loads were unrelated to anti-EBV IgG or IgA levels, as measured by VCA-p18 and EBNA1-specific synthetic peptide-based enzyme-linked immunosorbent assays. The presence of circulating tumor cells was assessed by amplification of BamHI-A rightward frame 1 (BARF1) mRNA, a viral oncogene abundantly expressed in EBV-carrying carcinomas but virtually absent from EBV-associated lymphomas. Despite high EBV DNA loads and the presence of EBNA1 and human U1A small nuclear ribonucleoprotein mRNA, BARF1 mRNA was never detected in blood. We conclude that amplicon size significantly influences EBV DNA load measurement in NPC patients. The circulating EBV DNA load is independent of serological parameters and does not reflect intact tumor cells. The primary diagnostic value of the EBV DNA load for the detection of NPC is limited.
引用
收藏
页码:3066 / 3073
页数:8
相关论文
共 15 条
  • [1] Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma
    Shao, JY
    Li, YH
    Gao, HY
    Wu, QL
    Cui, NJ
    Zhang, L
    Cheng, G
    Hu, LF
    Ernberg, I
    Zeng, YX
    CANCER, 2004, 100 (06) : 1162 - 1170
  • [2] Single-assay combination of Epstein-Barr virus (EBV) EBNA1-and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: Options for field screening
    Fachiroh, J
    Paramita, DK
    Hariwiyanto, B
    Harijadi, A
    Dahlia, HL
    Indrasari, SR
    Kusumo, H
    Zeng, YS
    Schouten, T
    Mubarika, S
    Middeldorp, JM
    JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (04) : 1459 - 1467
  • [3] Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA
    Stevens, Servi J. C.
    Verkuijlen, Sandra A. W. M.
    Hariwiyanto, Bambang
    Harijadi
    Paramita, Dewi K.
    Fachiroh, Jajah
    Adham, Marlinda
    Tan, I. Bing
    Haryana, Sophia M.
    Middeldorp, Jaap M.
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (03) : 608 - 614
  • [4] MODE OF REACTION OF ANTI-EBV ANTIBODY FROM PATIENTS WITH BURKITTS LYMPHOMA OR NASOPHARYNGEAL CANCER AGAINST EPSTEIN-BARR VIRUS
    SUZUKI, I
    HOSHINO, M
    JOURNAL OF ELECTRON MICROSCOPY, 1971, 20 (03): : 239 - &
  • [5] Specific IgA antibody to Epstein-Barr viral capsid antigen: A better marker for screening nasopharyngeal carcinoma than EBV-DNA detection by polymerase chain reaction
    Kantakamalakul, W
    Chongkolwatana, C
    Naksawat, P
    Muangsomboon, S
    Sukpanichnant, S
    Chongvisal, S
    Metheetrairat, C
    Kositanont, U
    Puthavathana, P
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2000, 18 (04): : 221 - 226
  • [6] Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma
    Lit, LCW
    Chan, KCA
    Leung, SF
    Lei, KIK
    Chan, LYS
    Chow, KCK
    Chan, ATC
    Lo, YMD
    CLINICAL CHEMISTRY, 2004, 50 (10) : 1842 - 1845
  • [7] DEMONSTRATION OF THE SERUM ANTIBODY TO EPSTEIN-BARR-VIRUS SPECIFIC DNA-POLYMERASE (EBV-DP) FROM PATIENTS WITH NASOPHARYNGEAL CARCINOMA (NPC)
    TAN, RS
    LI, JS
    GRILL, S
    NUTTER, LM
    CHENG, YC
    FEDERATION PROCEEDINGS, 1986, 45 (04) : 946 - 946
  • [8] Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody
    Leung, SF
    Tam, JS
    Chan, ATC
    Zee, B
    Chan, LYS
    Huang, DP
    Van Hasselt, A
    Johnson, PJ
    Lo, YMD
    CLINICAL CHEMISTRY, 2004, 50 (02) : 339 - 345
  • [9] Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen
    Mo Wu-ning
    Tang An-zhou
    Zhou Ling
    Huang Guang-wu
    Wang Zhan
    Zeng Yi
    CHINESE MEDICAL JOURNAL, 2009, 122 (10) : 1173 - 1178
  • [10] Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with Undifferentiated Carcinoma of Nasopharyngeal Type
    Bortolin, MT
    Pratesi, C
    Dolcetti, R
    Bidoli, E
    Vaccher, E
    Zanussi, S
    Tedeschi, R
    De Paoli, P
    CANCER LETTERS, 2006, 233 (02) : 247 - 254